BioAge Labs Presents Preclinical Data for Apelin Receptor Agonist Azelaprag for Obesity Demonstrating Significant Improvements in Weight Loss and Body Composition When Combined with Incretin Drugs
BioAge Labs Announces Inaugural Scientific Advisory Board to Support Advancement of Novel Therapeutics Targeting Metabolic Aging
Feb 13 (Reuters) - BioAge Labs, a biotech startup collaborating with Eli Lilly (LLY.N), opens new tab for trialing its obesity therapy, said on Tuesday it had raised $170 million in its latest funding round.
Until last year, BioAge Labs' progress could be best described as a slow burn, with a pipeline of longevity-focused medicines taking shape incrementally but consistently.
BioAge Announces Plans for Phase 2 of BGE-105 Co-Administered With Tirzepatide
BioAge Labs has garnered the support of Eli Lilly to run a trial combining a muscle regeneration therapy with the Big Pharma’s tirzepatide for healthier weight loss.
RICHMOND, Calif.--(BUSINESS WIRE)--BioAge Labs, Inc., a clinical-stage biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, today announced the appointment of BJ Sullivan, Ph.D., as Chief Strategy Officer. Sullivan is the first to hold the position at BioAge.
RICHMOND, Calif.--(BUSINESS WIRE)--BioAge Labs, Inc. (“BioAge”), a privately held clinical-stage biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, today announced that the company will provide updates on the company's progress in novel target identification and drug development in the brain aging area at upcoming conferences in the US and UK.
BioAge Hosting Webcast to Discuss Newly Announced Phase 1b Data Demonstrating BGE-105 Significantly Improves Muscle Atrophy in Older Volunteers on Bed Rest and Detail Phase 2 Plans
BioAge Labs has reported positive data from a Phase Ib clinical trial of apelin receptor APJ agonist BGE-105 to treat muscle atrophy.